1. Home
  2. TECX vs ENGN Comparison

TECX vs ENGN Comparison

Compare TECX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc. Common Stock

TECX

Tectonic Therapeutic Inc. Common Stock

HOLD

Current Price

$20.98

Market Cap

359.0M

Sector

N/A

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$8.22

Market Cap

379.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECX
ENGN
Founded
2019
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
359.0M
379.3M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
TECX
ENGN
Price
$20.98
$8.22
Analyst Decision
Strong Buy
Buy
Analyst Count
5
7
Target Price
$81.20
$22.71
AVG Volume (30 Days)
407.9K
3.3M
Earning Date
11-06-2025
12-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.70
$2.65
52 Week High
$61.07
$11.14

Technical Indicators

Market Signals
Indicator
TECX
ENGN
Relative Strength Index (RSI) 59.16 56.68
Support Level $18.60 $7.65
Resistance Level $22.00 $8.29
Average True Range (ATR) 1.72 0.66
MACD 0.09 0.07
Stochastic Oscillator 78.88 66.09

Price Performance

Historical Comparison
TECX
ENGN

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: